Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease-Reference-Cited by-同舟云学术

Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease

Published:2023-02-06 Issue:4 Volume:64 Page:846-855
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Sanber Khaled¹^ORCID,Ye Kevin²,Tsai Hua-Ling¹,Newman Matthew³,Webster Jonathan A.¹^ORCID,Gojo Ivana¹,Ghiaur Gabriel¹,Prince Gabrielle T.¹,Gondek Lukasz P.¹,Smith B. Douglas¹,Levis Mark J.¹,DeZern Amy E.¹,Ambinder Alexander J.¹,Dalton William B.¹^ORCID,Jain Tania¹^ORCID

Affiliation:

1. Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA

2. Johns Hopkins University School of Medicine, Baltimore, MD, USA

3. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital Department of Pharmacy, Baltimore, MD, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2173523

Reference32 articles.

1. Accelerated and Blast Phase Myeloproliferative Neoplasms

2. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms

3. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase

4. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

5. Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance;International Journal of Molecular Sciences;2023-12-29

2. How I treat transplant-eligible patients with myelofibrosis;Blood;2023-11-16

3. Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration;Haematologica;2023-07-06